RD13-02 CAR-T Cell Injection for Patients With r/r CD7+ T-ALL/T-LBL

EARLY_PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2023

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2024

Conditions

NeoplasmsHematologic NeoplasmsHematologic Diseases

Interventions

DRUG

RD13-02 cell infusion

CAR-T cells

Trial Locations (1)

The First Affiliated Hospital of University of Science and Technology of China, Hefei

All Listed Sponsors

collaborator

Nanjing Bioheng Biotech Co., Ltd.

INDUSTRY

lead

Xiaoyu Zhu

OTHER_GOV